Search
How to apply for an EHA Kick-off Grant
On this page, we explain all of the actions you'll need to take when submitting an EHA Kick-off Grant application.
Read morePresidential Speakers
Promising crucial developments in the field of hematology, the speakers and presentation topics of the EHA2025 Presidential Session speakers are now available.
Friday, June 13, 2025 - Presidential Session I
Immunotherapy (TCR related)
Prof.
Anna Vardi Physician Scientist Research Grant winner 2018
Please tell us more about yourself (name, lab, short bio)
I am Anna Vardi. I am currently working as a Consultant Hematologist at the Hematology Department and HCT Unit, G. Papanikolaou Hospital, Thessaloniki, Greece, under the Directorship of Dr.
How to apply for an EHA Innovation Grant
On this page, we explain all of the actions you'll need to take when submitting an EHA Innovation Grant application.
Read moreWhat to expect
FacultyThe faculty is made up of international leaders in clinical hematology research, statisticians, experts in regulatory and ethical aspects of clinical research and more.
Read moreClinical Research Training in Hematology
The CRTH 2025 call for applications is now closed. What is Clinical Research Training in Hematology (CRTH)?Clinical Research Training in Hematology (CRTH) provides early-career researchers with a unique, 9-month long training and mentoring experience.
Read moreWhat an EHA Innovation Grant supports
Our EHA Innovation Grant supports high-quality clinical or translational research in hematology. To reflect the collaborative spirit of the grant, no more than 40% of the total grant should be allocated to one member of the consortium.
Read moreWhat an EHA Bilateral Collaborative Grant supports
Our EHA Bilateral Collaborative Grant supports basic and translational lab-based research in hematology. To reflect the collaborative spirit of the grant, the budget must be divided 50:50 between the two PIs.
Read moreTreatment of acute lymphoblastic leukemia by activation of patient's immune cells by a bispecific antibody.
Abstract S722
Acute lymphoblastic leukemia (ALL) is a rare type of blood cancer which is mainly treated by intensive chemotherapy.
- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- »